New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...

J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

They suggest other fast-acting antidepressants could offer a competitive challenge to J&J's drug, including Axsome Therapeutics' recently approved Auvelity (bupropion/dextromethorphan), Sage ...

In 2024, the sale of antidepressant drugs in Russia increased by 20%, reaching 16.1 million packages by November, according ...

There has been a new antidepressant on the market every two or three years. In 1987, the antidepressant fluoxetine (Prozac) was introduced. It had been tested by the FDA and found to be an ...

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on AXSM stock, giving a Buy rating on January 15.Stay Ahead of ...

Antidepressant sales in Russia hit an all-time high last year, with 16.1 million packages of the medication sold between ...

Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Brexpiprazole tablets, used in ...

Alembic Pharmaceuticals has received USFDA approval for its generic version of Brexpiprazole tablets, used to treat major ...